Cancer Research Annual Meeting 2010 Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dolled-Filhart, M.
Right arrow Articles by Rimm, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dolled-Filhart, M.
Right arrow Articles by Rimm, D. L.
[Cancer Research 66, 5487-5494, May 15, 2006]
© 2006 American Association for Cancer Research

Clinical Research

Quantitative In situ Analysis of ß-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome

Marisa Dolled-Filhart, Anthony McCabe, Jennifer Giltnane, Melissa Cregger, Robert L. Camp and David L. Rimm

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut

Requests for reprints: David L. Rimm, Department of Pathology, Yale University School of Medicine, 310 Cedar Street, PO Box 208023, New Haven, CT 06520-8023. Phone: 203-737-4204; Fax: 203-737-5089; E-mail: david.rimm{at}yale.edu.

The role of ß-catenin in breast cancer and its prognostic value is controversial. The prognostic value had been assessed previously in a series of nonquantitative immunohistochemical studies with conflicting results. In efforts to clarify the relationship between ß-catenin protein expression and breast cancer prognosis, we have assessed a retrospective 600 case cohort of breast cancer tumors from the Yale Pathology archives on tissue microarrays. They were assessed using automated quantitative analysis (AQUA) with a series of array-embedded cell lines for which the ß-catenin concentration was standardized by an ELISA assay. The expression levels of the standard clinical markers HER2, estrogen receptor (ER), progesterone receptor (PR), and Ki-67 were also assessed on the same cohort. X-tile software was used to select optimal protein concentration cutpoints and to evaluate the outcome using a training set and a validation set. We found that low-level expression of membranous ß-catenin is associated with significantly worse outcome (38% versus 76%, 10-year survival, validation set log-rank P = 0.0016). Multivariate analysis of this marker, assessed in a proportional hazards model with tumor size, age, node status, nuclear grade, ER, PR, HER2, and Ki-67, is still highly significant with a hazard ratio of 6.8 (P < 0.0001, 95% confidence interval, 3.1-15.1). These results suggest that loss of ß-catenin expression at the membrane, as assessed by objective quantitative analysis methods, may be useful as a prognostic marker or may be part of a useful algorithm for prognosis in breast cancer. (Cancer Res 2006; 66(10): 5487-94)




This article has been cited by other articles:


Home page
 Cancer Prevention ResearchHome page
G. Murillo, X. Peng, K. E.O. Torres, and R. G. Mehta
Deguelin Inhibits Growth of Breast Cancer Cells by Modulating the Expression of Key Members of the Wnt Signaling Pathway
Cancer Prevention Research, November 1, 2009; 2(11): 942 - 950.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. B. Jilaveanu, C. R. Zito, S. A. Aziz, P. J. Conrad, J. C. Schmitz, M. Sznol, R. L. Camp, D. L. Rimm, and H. M. Kluger
C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas
Clin. Cancer Res., September 15, 2009; 15(18): 5704 - 5713.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. Nadler, A. M. Gonzalez, R. L. Camp, D. L. Rimm, H. M. Kluger, and Y. Kluger
Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer
Ann. Onc., August 28, 2009; (2009) mdp346v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Medrek, G. Landberg, T. Andersson, and K. Leandersson
Wnt-5a-CKI{alpha} Signaling Promotes {beta}-Catenin/E-Cadherin Complex Formation and Intercellular Adhesion in Human Breast Epithelial Cells
J. Biol. Chem., April 17, 2009; 284(16): 10968 - 10979.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M Seppala, H Koistinen, R Koistinen, L Hautala, P C Chiu, and W S Yeung
Glycodelin in reproductive endocrinology and hormone-related cancer
Eur. J. Endocrinol., February 1, 2009; 160(2): 121 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Jilaveanu, C. Zito, S. J. Lee, K. L. Nathanson, R. L. Camp, D. L. Rimm, K. T. Flaherty, and H. M. Kluger
Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
Clin. Cancer Res., February 1, 2009; 15(3): 1076 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. L. Camp, V. Neumeister, and D. L. Rimm
A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers
J. Clin. Oncol., December 1, 2008; 26(34): 5630 - 5637.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Safholm, J. Tuomela, J. Rosenkvist, J. Dejmek, P. Harkonen, and T. Andersson
The Wnt-5a-Derived Hexapeptide Foxy-5 Inhibits Breast Cancer Metastasis In vivo by Targeting Cell Motility
Clin. Cancer Res., October 15, 2008; 14(20): 6556 - 6563.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Nadler, R. L. Camp, C. Schwartz, D. L. Rimm, H. M. Kluger, and Y. Kluger
Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer
Clin. Cancer Res., July 15, 2008; 14(14): 4455 - 4462.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Hayes, D. Thomas, A. Emmons, T. J. Giordano, and C. G. Kleer
Genetic Changes of Wnt Pathway Genes Are Common Events in Metaplastic Carcinomas of the Breast
Clin. Cancer Res., July 1, 2008; 14(13): 4038 - 4044.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
G. M. Kreizenbeck, A. J. Berger, A. Subtil, D. L. Rimm, and B. E. Gould Rothberg
Prognostic Significance of Cadherin-Based Adhesion Molecules in Cutaneous Malignant Melanoma
Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 949 - 958.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Plotnikov, Y. Li, T. H. Tran, W. Tang, J. P. Palazzo, H. Rui, and S. Y. Fuchs
Oncogene-Mediated Inhibition of Glycogen Synthase Kinase 3{beta} Impairs Degradation of Prolactin Receptor
Cancer Res., March 1, 2008; 68(5): 1354 - 1361.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. B. Moeder, J. M. Giltnane, M. Harigopal, A. Molinaro, A. Robinson, K. Gelmon, D. Huntsman, R. L. Camp, and D. L. Rimm
Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray Based Assessment of Outcome
J. Clin. Oncol., December 1, 2007; 25(34): 5418 - 5425.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Wang, D. Teske, A. Tess, R. Kohlhepp, Y. Choi, C. Kendziorski, and A. R. Moser
Identification of Novel Modifier Loci of ApcMin Affecting Mammary Tumor Development
Cancer Res., December 1, 2007; 67(23): 11226 - 11233.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. B. Seligson, F. Hongo, S. Huerta-Yepez, Y. Mizutani, T. Miki, H. Yu, S. Horvath, D. Chia, L. Goodglick, and B. Bonavida
Expression of X-Linked Inhibitor of Apoptosis Protein Is a Strong Predictor of Human Prostate Cancer Recurrence
Clin. Cancer Res., October 15, 2007; 13(20): 6056 - 6063.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Giltnane, L. Ryden, M. Cregger, P.-O. Bendahl, K. Jirstrom, and D. L. Rimm
Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor Positive Premenopausal Breast Cancer
J. Clin. Oncol., July 20, 2007; 25(21): 3007 - 3014.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. Huang, G. P. Casale, J. Tian, N. K. Wehbi, N. A. Abrahams, Z. Kaleem, L. M. Smith, S. L. Johansson, J. E. Elkahwaji, and G. P. Hemstreet III
Quantitative Fluorescence Imaging Analysis for Cancer Biomarker Discovery: Application to {beta}-Catenin in Archived Prostate Specimens
Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1371 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Rimm, J. M. Giltnane, C. Moeder, M. Harigopal, G. G. Chung, R. L. Camp, and B. Burtness
Bimodal Population or Pathologist Artifact?
J. Clin. Oncol., June 10, 2007; 25(17): 2487 - 2488.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Pick, Y. Kluger, J. M. Giltnane, C. Moeder, R. L. Camp, D. L. Rimm, and H. M. Kluger
High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer
Cancer Res., April 1, 2007; 67(7): 2932 - 2937.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.